IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
IGC Pharma Reports First Quarter Fiscal 2025 Results
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
IGC Pharma announced patient enrollment at Neurostudies, Inc. in Port Charlotte, Florida, for its Phase 2 clinical trial investigating IGC-AD1 as a potential treatment for Agitation in Alzheimer's disease.